Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting
06 juin 2022 16h15 HE
|
Delcath Systems, Inc.
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response...
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update
10 mai 2022 07h30 HE
|
Delcath Systems, Inc.
NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
09 mai 2022 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems to Host First Quarter 2022 Results
28 avr. 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
08 avr. 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will...
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
29 mars 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
25 mars 2022 07h30 HE
|
Delcath Systems, Inc.
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
15 mars 2022 16h30 HE
|
Delcath Systems, Inc.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Present at the 34th Annual Roth Conference
10 mars 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will...
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe
02 mars 2022 16h01 HE
|
Delcath Systems, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is...